Recent trials into retatrutide, a dual GIP and GLP-1 agonist , are demonstrating significant benefits for metabolic management . Early clinical investigations have revealed substantial losses in body size and improvements in related health factors, especially for individuals with overweight . Planned pursuits center on assessing the long-term secur